TSX:ONC 0.54 CAD -0.01 -1.82% Volume: 81,061 October 24, 2014
NASDAQ:ONCY 0.48 USD -0.01 -2.79% Volume: 149,778 October 24, 2014

A Novel Approach to Cancer Therapeutics

Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics’ clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.

Latest News

October 24, 2014 Oncolytics Biotech® Inc. Announces Entry Into $20 Million "At-The-Market" Equity Distribution Agreement with Canaccord Genuity Inc.
October 20, 2014 Oncolytics Biotech® Inc. Announces Amendment to Common Share Purchase Agreement with Lincoln Park Capital Fund, LLC
September 16, 2014 Oncolytics Biotech® Inc. Announces Overall and KRAS-Mutated Patient Data from U.S. Randomized Phase 2 Pancreatic Cancer Study
Sign up to receive e-mail updates *